<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02273635</url>
  </required_header>
  <id_info>
    <org_study_id>14PIE-26946CORFO</org_study_id>
    <secondary_id>14-391</secondary_id>
    <nct_id>NCT02273635</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MS</brief_title>
  <official_title>Controlled, Randomized, Double-blind Clinical Trial, 24 Months Duration, to Compare the Efficacy, Safety and Tolerability of Andrographolide Versus Placebo in Patients With Progressive Forms of Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innobioscience SpA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pontificia Universidad Catolica de Chile</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Chile</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universidad Austral de Chile</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Innobioscience SpA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy and safety of andrographolide 140 mg
      administered twice a day orally versus a placebo as a modifying treatment of the disease in
      patients with the progressive forms of Multiple Sclerosis (MS).

      The principal outcome is to determine the efficacy, of andrographolide in retarding the
      progression of brain atrophy in patients with progressive forms of MS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Evaluate the clinical efficacy of andrographolide 140 mg administered orally twice a day
           versus a placebo in:

             -  Delay in the disability capacity progression through the Expanded Disability Status
                Scale (EDSS) and Multiple Sclerosis Functional Composite (MSFC) at 24 months
                compared to the baseline.

             -  Delay in cognitive impairment by means of Paced Auditory Serial Addition Test
                (PASAT), Symbol Digit Modalities Test (SDMT) and depression (Beck) at 24 months
                compared to the baseline.

             -  Quality of life Multiple Sclerosis Impact Scale (MSIS 29) and fatigue (Krupp)
                through parameters reported by the patients at at 24 months compared to the
                baseline.

             -  Tolerability of andrographolide measured by the Treatment Satisfaction
                Questionnaire for Medication (TSQM) at 24 months.

             -  Delay in the decrease in brain volume measured by Magnetic Resonance (MR) at 24
                months compared to the baseline.

             -  Number and volume of new lesions or larger size in T2 by MR at 24 months compared
                to the baseline.

             -  Number of new hipointense lesions in T1 or (gadolinium captive) by MR at 24 months
                compared to the baseline.

             -  Delay in the retineal thinning measured by Optical Coherence Tomography (OCT) and
                visual field at 24 months compared to the baseline.

             -  Safety of andrographolide at 24 months through the record of adverse effects in
                symptom dairy and programmed interviews.

        2. Explore the pharmacokinetic of andrographolide 140 mg administered orally twice day in:

             -  bio availability and concentration of andrographolide in the patients with
                treatment.

             -  half-life, maximum concentration, clearance of andrographolide in equilibrium
                state.

        3. Determine the immunomodulatory effects of andrographolide 140 mg administered twice a
           day orally on lymphocyte populations in patients through the:

             -  Determination of Th1, Th2, Th17 and Treg lymphocyte sub-populations.

             -  Determination of cytokines IFNgama, TNFalpha, IL2, IL17alpha and TGFbeta.

      Population: adult patients, men and women with progressive forms of MS. The number of
      patients to be selected will be 68, to randomly assign 34 patients to each group.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">April 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Brain atrophy in patients with progressive forms of MS</measure>
    <time_frame>24 months</time_frame>
    <description>Retarding the progression of brain atrophy as measured by MR quantified by the percentage of change in volume size utilizing SIENA.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Expanded Disability Status Scale (EDSS)</measure>
    <time_frame>24 months</time_frame>
    <description>Delay in the disability capacity progression through the Expanded Disability Status Scale (EDSS) at 24 months compared to the baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Paced Auditory Serial Addition Test (PASAT)</measure>
    <time_frame>24 months</time_frame>
    <description>Delay in cognitive impairment by means of Paced Auditory Serial Addition Test (PASAT) at 24 months compared to the baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life Multiple Sclerosis Impact Scale (MSIS 29)</measure>
    <time_frame>24 months</time_frame>
    <description>Quality of life Multiple Sclerosis Impact Scale (MSIS 29) through parameters reported by the patients at 24 months compared to the baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment Satisfaction Questionnaire for Medication (TSQM)</measure>
    <time_frame>24 months</time_frame>
    <description>Tolerability of andrographolide measured by the Treatment Satisfaction Questionnaire for Medication (TSQM) at 24 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of new T2 lesions</measure>
    <time_frame>24 months</time_frame>
    <description>Number of new lesions T2 by MR at 24 months compared to the baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New hypointense lesions in T1</measure>
    <time_frame>24 months</time_frame>
    <description>Number of new hypointense lesions in T1 by MR at 24 months compared to the baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical Coherence Tomography (OCT)</measure>
    <time_frame>24 months</time_frame>
    <description>Delay in the retinal thinning measured by Optical Coherence Tomography (OCT) at 24 months compared to the baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Record of adverse effects in daily symptoms and programmed interviews.</measure>
    <time_frame>24 months</time_frame>
    <description>Safety of andrographolide at 24 months through the record of adverse effects in daily symptoms and programmed interviews.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple Sclerosis Functional Composite (MSFC)</measure>
    <time_frame>24 months</time_frame>
    <description>Delay in the disability capacity progression through the Multiple Sclerosis Functional Composite (MSFC) at 24 months compared to the baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symbol Digit Modalities Test (SDMT)</measure>
    <time_frame>24 months</time_frame>
    <description>Delay in cognitive impairment by means of Symbol Digit Modalities Test (SDMT) at 24 months compared to the baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression by Beck scale</measure>
    <time_frame>24 months</time_frame>
    <description>Evaluate mood disorders by means of Beck scale at 24 months compared to the baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue by Krupp scale</measure>
    <time_frame>24 months</time_frame>
    <description>Evaluate fatigue by Krupp scale reported by the patients at 24 months compared to the baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of new gadolinium enhancement lesions in T1 by MR</measure>
    <time_frame>24 months</time_frame>
    <description>Number of new gadolinium enhancement lesions in T1 by MR at 24 months compared to the baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual field</measure>
    <time_frame>24 months</time_frame>
    <description>Change in visual field at 24 months compared to the baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of new T2 lesions</measure>
    <time_frame>24 months</time_frame>
    <description>Volume of size in T2 by MR at 24 months compared to the baseline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Primary Progressive Multiple Sclerosis</condition>
  <condition>Multiple Sclerosis, Secondary Progressive</condition>
  <arm_group>
    <arm_group_label>andrographolides</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Coated tablets containing 140 mg andrographolides twice a day orally administered for a period of 24 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>sugar tablets</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Coated tablets containing 140 mgs excipients twice a day orally administered for a period of 24 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Andrographolides</intervention_name>
    <description>140 mg andrographolides coated tablets twice a day orally administered for 24 months.</description>
    <arm_group_label>andrographolides</arm_group_label>
    <other_name>andrographolide, neoandrographolide, deoxyandrographolide</other_name>
    <other_name>IB-MS 14</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>140 mg excipients coated tablets twice a day orally administered for 24 months</description>
    <arm_group_label>sugar tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed Informed Consent previous to the initiation of the study before any evaluation.

          -  Men and women &gt; 18 years of age with Minimental &gt; 24.

          -  Patients with diagnosis of secondary progressive MS without relapses or primary
             progressive MS according to the criteria of McDonald 2010.

        Exclusion Criteria:

          -  Relapsing-remitting MS

          -  Current Immunomodulatory or immunosuppressive therapy

          -  Uncontrolled systemic diseases not controlled or treated with immunotherapy (i.e
             Rheumatoid Arthritis, Lupus Erythematosus).

          -  Pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan L Hancke, DVM, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Universidad Austral de Chile</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Claudia A Carcamo, MD, PhD</last_name>
    <phone>+56223546885</phone>
    <email>ccarcamo@med.puc.cl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ethel L Ciampi, MD</last_name>
    <phone>+56223546885</phone>
    <email>anticsnap@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Multiple Sclerosis Centre, Pontificia Universidad Catolica de Chile</name>
      <address>
        <city>Santiago</city>
        <state>Metropolitana</state>
        <zip>8330033</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudia A Carcamo, MD, PhD.</last_name>
      <phone>56 2 3546885</phone>
      <email>ccarcamo@med.puc.cl</email>
    </contact>
    <contact_backup>
      <last_name>Ana C Reyes, Nurse</last_name>
      <phone>56 2 3546885</phone>
      <email>acreyes@med.puc.cl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Chile</country>
  </location_countries>
  <reference>
    <citation>Iruretagoyena MI, Tobar JA, González PA, Sepúlveda SE, Figueroa CA, Burgos RA, Hancke JL, Kalergis AM. Andrographolide interferes with T cell activation and reduces experimental autoimmune encephalomyelitis in the mouse. J Pharmacol Exp Ther. 2005 Jan;312(1):366-72. Epub 2004 Aug 26.</citation>
    <PMID>15331658</PMID>
  </reference>
  <reference>
    <citation>Iruretagoyena MI, Sepúlveda SE, Lezana JP, Hermoso M, Bronfman M, Gutiérrez MA, Jacobelli SH, Kalergis AM. Inhibition of nuclear factor-kappa B enhances the capacity of immature dendritic cells to induce antigen-specific tolerance in experimental autoimmune encephalomyelitis. J Pharmacol Exp Ther. 2006 Jul;318(1):59-67. Epub 2006 Apr 5.</citation>
    <PMID>16597709</PMID>
  </reference>
  <reference>
    <citation>Burgos RA, Hancke JL, Bertoglio JC, Aguirre V, Arriagada S, Calvo M, Cáceres DD. Efficacy of an Andrographis paniculata composition for the relief of rheumatoid arthritis symptoms: a prospective randomized placebo-controlled trial. Clin Rheumatol. 2009 Aug;28(8):931-46. doi: 10.1007/s10067-009-1180-5. Epub 2009 Apr 29.</citation>
    <PMID>19408036</PMID>
  </reference>
  <reference>
    <citation>Cabrera D, Gutiérrez J, Cabello-Verrugio C, Morales MG, Mezzano S, Fadic R, Casar JC, Hancke JL, Brandan E. Andrographolide attenuates skeletal muscle dystrophy in mdx mice and increases efficiency of cell therapy by reducing fibrosis. Skelet Muscle. 2014 Mar 21;4:6. doi: 10.1186/2044-5040-4-6. eCollection 2014.</citation>
    <PMID>24655808</PMID>
  </reference>
  <reference>
    <citation>Carretta MD, Alarcón P, Jara E, Solis L, Hancke JL, Concha II, Hidalgo MA, Burgos RA. Andrographolide reduces IL-2 production in T-cells by interfering with NFAT and MAPK activation. Eur J Pharmacol. 2009 Jan 14;602(2-3):413-21. doi: 10.1016/j.ejphar.2008.11.011. Epub 2008 Nov 13.</citation>
    <PMID>19038244</PMID>
  </reference>
  <reference>
    <citation>Burgos RA, Seguel K, Perez M, Meneses A, Ortega M, Guarda MI, Loaiza A, Hancke JL. Andrographolide inhibits IFN-gamma and IL-2 cytokine production and protects against cell apoptosis. Planta Med. 2005 May;71(5):429-34.</citation>
    <PMID>15931581</PMID>
  </reference>
  <reference>
    <citation>Hidalgo MA, Romero A, Figueroa J, Cortés P, Concha II, Hancke JL, Burgos RA. Andrographolide interferes with binding of nuclear factor-kappaB to DNA in HL-60-derived neutrophilic cells. Br J Pharmacol. 2005 Mar;144(5):680-6.</citation>
    <PMID>15678086</PMID>
  </reference>
  <reference>
    <citation>Sandborn WJ, Targan SR, Byers VS, Rutty DA, Mu H, Zhang X, Tang T. Andrographis paniculata extract (HMPL-004) for active ulcerative colitis. Am J Gastroenterol. 2013 Jan;108(1):90-8. doi: 10.1038/ajg.2012.340. Epub 2012 Oct 9.</citation>
    <PMID>23044768</PMID>
  </reference>
  <reference>
    <citation>Tang T, Targan SR, Li ZS, Xu C, Byers VS, Sandborn WJ. Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis - a double-blind comparison with sustained release mesalazine. Aliment Pharmacol Ther. 2011 Jan;33(2):194-202. doi: 10.1111/j.1365-2036.2010.04515.x. Epub 2010 Nov 30.</citation>
    <PMID>21114791</PMID>
  </reference>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2014</study_first_submitted>
  <study_first_submitted_qc>October 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2014</study_first_posted>
  <last_update_submitted>October 24, 2014</last_update_submitted>
  <last_update_submitted_qc>October 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Chronic Progressive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Andrographolide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

